4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe
January 21 2021 - 6:00AM
Business Wire
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutic products (LBPs) - a novel class
of drug derived from the microbiome, today announced its
participation in the Microbiome Movement Drug Development Summit –
Europe, including the Plenary Session, Microbiome Leaders Industry
Review Panel.
- Plenary Session: European Microbiome Leaders Panel
Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am
ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
- Clinical Trial Design and Evaluating PK/PD Session: MicroRx®
and Single Strain Live Biotherapeutics: Proof of Concept Clinical
Data and Future Considerations on Thursday, January 28, 2021 at
11:30pm GMT (6:30am ET) with Research Director, Dr. Imke
Mulder
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx®, that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalized with COVID-19, and Blautix® in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programs include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210121005114/en/
4D pharma Duncan Peyton, Chief Executive Officer +44 (0)113 895
0130 Investor Relations: ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20
7496 3000 Philip Davies / Justin McKeegan / Iqra Amin (Corporate
Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20
7332 2500 Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200 Julie
Seidel Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter
/ Michelle Boxall
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024